ReviewFrontiers in immunology2026
Soluble CTLA-4 as a context-dependent immune checkpoint: biology, biomarker potential, and therapeutic implications.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) exists not only as a membrane-bound immune checkpoint but also as a naturally secreted soluble isoform (sCTLA-4), generated primarily through exon 3 skipping. This review focuses specifically on splice-derived sCTLA-4 and examines its biological and clinical significance. sCTLA-4 is shaped by immune state, cellular source, and tissue microenvironment. Mechanistically, sCTLA-4 can restrain B7/CD28-dependent immune activation, while recent preclinical evidence suggests a preferential effect on type 1 immune responses. In autoimmune and inflammatory diseases, longitudinal changes in sCTLA-4 often parallel changes in immune activity, although its performance as a disease-specific biomarker remains limited. In cancer, associations with tumor burden, prognosis, and treatment response are more variable and appear to depend strongly on the surrounding immune context. Thus, circulating sCTLA-4 may be better viewed as a state-dependent immunoregulatory signal than as a universal standalone biomarker. Current evidence does not clearly establish whether its elevation is causal, compensatory, or epiphenomenal. Key translational priorities include detection methods that distinguish sCTLA-4 isoforms and cellular sources, standardized longitudinal sampling, biomarker panels that integrate sCTLA-4 with defined immune phenotypes, and therapeutic strategies tailored to specific immune contexts while preserving peripheral tolerance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.